Back
Rocket Pharmaceuticals Inc (RCKT)
BiotechnologyRCKT · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$2.57
−1.91%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-2.01
ROE
-64.4%
Gross margin
0.0%
Debt/Equity
0.10x
Revenue growth
P/B ratio
Beta
Forward P/E
Rocket Pharmaceuticals Inc — company intelligence
Earnings surprises
Q2 2026$-0.48 vs $0.25 est-294.6%
Q1 2026$-0.42 vs $-0.42 est-1.2%
Q4 2025$-0.38 vs $-0.46 est+17.8%
Q3 2025$-0.45 vs $-0.52 est+12.6%
Analyst consensus · 20 analysts
11 Buy7 Hold2 Sell
Updated Oct 10, 2026
Insider activity · 90 days
2 buys2 sellsnet +133,382 shares
Chaudhuri SarbaniSell 4,701 · Aug 11, 2026
Stevens Christopher JamesSell 36,658 · Aug 11, 2026
SOUTHWELL DAVID Pgift 150,000 · Aug 3, 2026
Recent SEC filings
8-K — Material event reportSep 15, 2026
4 — Insider transaction reportSep 15, 2026
8-K — Material event reportAug 27, 2026
Latest news
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday — Benzinga · 2d ago
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4 — Benzinga · 2d ago
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility — Yahoo · 3d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.